AGE1 | Activity | F4

Team Portfolio Raise Essays

F4/AGE1/Activity

AGE1 Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Essay

Published an essay on intervening in the aging immune system to reshape cancer prevention.

How the Aging Immune System Rewrites Cancer Prevention

librariesforthefuture.bioJUL 20, 2026

JUL 20, 2026

Team Change

Portfolio company Aerska strengthened leadership and board with key appointments to advance RNA medicines for the brain.

Aerska

AerskaAGE1

globenewswire.comAPR 15, 2026

APR 15, 2026

4 essays· FEB 2026Show all

Essay

Published a guide on the five key decisions between a validated target and a clinical program.

Founder's Playbook: From Target to Development Strategy

librariesforthefuture.bioFEB 22, 2026

FEB 22, 2026

Essay

age1 published a call for proposals identifying five unconquered frontiers: osteoarthritis, chronic kidney disease, delaying menopause, prevention of vision loss, and age-related cardiorespiratory deficit.

Age1

Age1AGE1

blog.age1.comFEB 16, 2026

FEB 16, 2026

Essay

Published a framework for enabling technologies in longevity biotech and solicited proposals for addressing five key frontiers in the field.

Five Unconquered Frontiers for Longevity biotech: Our 2026 Call for Proposals

librariesforthefuture.bioFEB 16, 2026

FEB 16, 2026

Essay

Published a framework for target validation in drug development before significant capital commitment.

The Cheapest Insurance in Drug Development

librariesforthefuture.bioFEB 15, 2026

FEB 15, 2026

Investment

Co-led Aerska's $39M Series A alongside EQT Dementia Fund to deliver RNA medicines to the brain.

Aerska

globenewswire.comFEB 9, 2026

FEB 9, 2026

Investment

Co-led Aerska's $39M Series A for brain shuttle technology to deliver RNA medicines to the brain for neurological diseases.

Aerska

AerskaAGE1

eqtgroup.comFEB 9, 2026

FEB 9, 2026

Essay

Published a strategic framework for context-preserving target discovery in biotech.

Hunting Targets in Their Native Environment

librariesforthefuture.bioFEB 7, 2026

FEB 7, 2026

Investment

Led Loyal's $100M Series C to advance the first canine longevity drug.

Loyalfordogs

Loyalfordogs AGE1

businesswire.comFEB 2026

FEB 2026